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Mechanistic understanding of secondary hyperpara-
thyroidism, vascular calcification, and regulation of
phosphate metabolism in chronic kidney disease (CKD) has
advanced significantly in the past five decades. In 1960,
Bricker developed the ‘intact nephron hypothesis’, opening
the door for hundreds of investigations. He emphasized that
‘as the number of functioning nephrons decreases, each
remaining nephron must perform a greater fraction of total
renal excretion’. Phosphate per se,i n d e p e n d e n to fC a
2þ and
calcitriol, directly affects the development of parathyroid
gland hyperplasia and secondary hyperparathyroidism.
Vitamin D receptor, Ca
2þ sensing receptor, and
Klotho–fibroblast growth factor (FGF) receptor-1 complex are
all significantly decreased in the parathyroid glands of
patients with CKD. Duodenal instillation of phosphate rapidly
decreases parathyroid hormone release without changes in
calcium or calcitriol. The same procedure also rapidly
increases renal phosphate excretion independently of
FGF-23, suggesting the possibility of an ‘intestinal
phosphatonin’. These observations suggest a possible
‘phosphate sensor’ in the parathyroid glands and
gastrointestinal tract, although as yet there is no proof for
the existence of such a sensor. Evidence shows that
phosphate has a key role in parathyroid hyperplasia by
activating the transforming growth factor-a–epidermal
growth factor receptor complex. Thus, control of serum
phosphorus early in the course of CKD will significantly
ameliorate the pathological manifestations observed during
progressive deterioration of renal function.
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In advancing chronic kidney disease (CKD), there is a
multitude of biochemical, physiological, and clinical altera-
tions. In the nineteenth century, Bright
1 recognized the
relationship between intrinsic kidney disease and the many
abnormalities seen in the uremic state. The exact nature of
events leading from the initial destruction of nephrons to the
pathophysiological changes of end-stage renal function was
not fully understood then. However, there is now signiﬁcant
evidence demonstrating that the many forms of CKD could
give rise to the same pattern of derangements that relate
principally to the extent of nephron destruction.
The physiopathology of ‘chronic Bright’s disease’, an
exposition of the ‘intact nephron hypothesis’ published
in Bricker et al.,
2 provided a logical framework for under-
standing the changes in renal function that occur in animal
models and in patients with CKD. Bricker et al. observed
adaptive changes in renal function and in homeostasis that
result from progressive CKD.
Bricker
3 emphasized that, as the number of functioning
nephrons decreases, each remaining nephron must perform a
greater fraction of total renal excretion. Bricker clearly explained
the differences between substances such as creatinine, which are
mainly handled by glomerular ﬁltration, and sodium and
phosphate, which are mainly handled by renal tubular
reabsorption. For substances handled by glomerular ﬁltration,
a decrease in glomerular ﬁltration induces a progressive increase
in their plasma concentration early in the course of CKD. On
the other hand, with substances such as sodium and phosphate
that are mainly handled by tubular reabsorption, a decrease in
renal tubular reabsorption of these substances will prevent a
signiﬁcant change in their blood concentrations, and their levels
will remain normal in serum until advanced deterioration of
renal function. Similarly, with substances such as potassium,
which are mainly handled by renal tubular secretion, adaptive
processes that will signiﬁcantly increase the potassium secretion
per nephron will maintain the levels of serum potassium within
the normal range despite the fact that the patient may have
severe renal impairment.
In the 1950s, if there was a consensus, ‘it was that the
processes of disease transformed the afﬂicted kidney into a
disorganized and heterogeneous population of nephrons
marred by a spectrum of functional disturbances which
varied from one kidney to another, from one disease to
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3 Bricker
3 elaborated in
great detail and challenged the idea that anatomical
abnormalities cannot be followed by functional adaptations.
He emphasized that ‘the functional capacity of the residual
nephrons of the diseased kidney is largely independent of the
speciﬁc form of renal disease. The decrease in the number of
nephrons is clearly responsible for many of the abnormalities
that develop in the patient; the persistent nephrons permit
the patient to survive.’ One of the best examples is related to
sodium excretion. A normal person with a glomerular
ﬁltration rate (GFR) of 120ml/min will ﬁlter 17,000 to
18,000mEq/day of Na. This person will excrete B1% of the
ﬁltered load of sodium provided the patient has a normal salt
intake (8–12 g/day).
If the patient with CKD continues with the same diet but
loses 50% of his/her renal function, the renal tubule must
adapt and excrete twice the amount of Na per nephron, or
roughly 2%. As the disease progresses, every time the patient
loses 50% of his renal function, the fractional excretion of
sodium should double. This hypothesis is depicted in
Figure 1. Studies by Slatopolsky et al.
4 validated this hypo-
thesis, comparing patients with normal GFRs (120ml/min)
with those with GFRs as low as 2.0ml/min (Figure 2). When
patients with inulin clearances from 25 to 2.6ml/min were
fed diets containing 60 or 120mEq/day of Na, all patients
were in perfect balance, clearly demonstrating that the lower
the GFR and consequently the lower the number of neph-
rons, the greater the fractional excretion of Na. In other
words, as GFR decreases, the greater the amount of Na excre-
ted per remaining nephron. This indicates that patients with
very low GFRs (o5ml/min) ingesting 120mEq/day of Na
must excrete 430% of the ﬁltered load of Na to maintain
sodium balance.
To further correlate the relationship between Na excretion
and bicarbonate reabsorption, Slatopolsky et al.
5 performed
bicarbonate titrations in patients with CKD stages 3–5. Nor-
mal subjects and patients with CKD with GFRs 430ml/min
fell into one group. When extracellular ﬂuid volume
expansion was minimized by salt deprivation and diuretics
in advance of the titration study, after the infusion of sodium
bicarbonate, no deﬁnitive maximal tubular reabsorption for
bicarbonate was observed. In the same group of patients,
exaggerated expansion of the extracellular ﬂuid led to an
alteration in the patterns of bicarbonate reabsorption. Results
from patients with GFRs of p20ml/min resembled increased
expansion, although extracellular ﬂuid volume expansion was
not exaggerated. However, those patients had a signiﬁcant
increase in Na excretion per nephron. On the other hand,
patients with severe CKD stage 5 and nephrotic syndrome
characterized by a low excretion of Na per nephron had a
maximal tubular reabsorption for bicarbonate similar to normal
subjects. There was a signiﬁcant correlation between fractional
excretion of sodium and bicarbonate reabsorption (Po0.0001;
ref. 5).
THE INTACT NEPHRON AND CKD-RELATED MINERAL AND
BONE DISORDER
CKD is characterized by several alterations in mineral
homeostasis. Secondary hyperparathyroidism is present even
in the early stages of CKD and leads to the development of
high bone turnover, pathological fractures, vascular calciﬁca-
tion, and other systemic alterations.
The maintenance of phosphate balance requires the
excretion into the urine each day of the same amount of
phosphorus that enters the extracellular ﬂuid.
3 Several
decades ago we demonstrated that, in dogs with experimental
renal disease and in patients with different degrees of CKD,
tubular reabsorption of phosphate decreases in proportion to
the severity of CKD. At a GFR of 120ml/min, B10% of the
ﬁltered phosphate is excreted (that is, tubular reabsorption of
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Figure 1|Hypothetical treatment of sodium excretion in
chronic kidney disease (see text for details). GFR, glomerular
filtration rate; FENa, fractional excretion of sodium; FLNa, filtered
load of sodium. Figure newly constructed from data in Bricker
et al.
2 and Bricker.
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Figure 2|Urinary sodium excretion in patients with advanced
chronic kidney disease (stages 4–5). All patients with glomerular
filtration rates ranging from 25 to 2.6ml/min maintain perfect Na
balance after ingestion of 60 or 120 mEq of Na/day. Reproduced
by permission from Slatopolsky et al.
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phosphate excretion per nephron increases, and at very low
ﬁltration rate levels tubular reabsorption of phosphate is
10–20%, or 80–90% of the ﬁltered load of phosphate is
excreted into the urine
6 (Figure 3).
In our initial studies in dogs with 5/6 nephrectomy,
7
we demonstrated that if we greatly restricted phosphate
intake from 1200 to 100mg/day there was no need for
adaptation, and the surviving nephrons could reabsorb
90% of the ﬁltered load of phosphate. Moreover, in the
same studies we demonstrated that, if phosphate is restricted
from the beginning of nephron reduction, secondary hyper-
parathyroidism can be prevented, suggesting a critical role for
phosphate retention in the elevation of parathyroid hormone
(PTH). Subsequently, we developed the concept of ‘propor-
tional reduction’. In other words, if GFR is reduced in a
step-wise manner over a period of weeks or months by
gradual ligation of the branches of the renal artery, and at the
same time phosphate intake is reduced in proportion to the
decrease in GFR, there is no need for adaptation. We clearly
demonstrated this hypothesis in a paper published in 1972
(ref. 8). In a group of dogs, GFR was gradually reduced from
56 to 40 to 19, and ﬁnally to 12ml/min. At the same time,
phosphate intake was gradually and proportionally reduced
from 1200 to 234mg/day. There were no changes in serum
phosphorus, calcium, magnesium, tubular reabsorption of
phosphate, or PTH, clearly indicating that we could prevent
the development of secondary hyperparathyroidism by
preventing the adaptation of phosphate excretion.
Subsequently, we learned the critical role of 1,25(OH)2D3
(calcitriol) in the transcriptional repression of the PTH
gene.
9,10 Because in advanced CKD the reduced renal mass
may limit the production of calcitriol, studies were cond-
ucted
11 to clarify whether phosphate restriction improves
secondary hyperparathyroidism in advanced CKD directly
or indirectly. Dogs with experimental CKD were fed a
low-calcium, low-phosphate diet for several weeks (Figure 4).
It is well known that a low-phosphate diet can increase the
levels of calcitriol, presumably by decreasing the levels of
ﬁbroblast growth factor (FGF)-23, which reduces the activity
of 1a-hydroxylase. The results conﬁrm a marked effect of
phosphate restriction in secondary hyperparathyroidism. In
humans and rats, calcium and phosphorus are well-known
modulators of renal 1a-hydroxylase. However, in contrast to
previous ﬁndings in patients with early CKD,
12 in the dogs
with advanced CKD, signiﬁcant reduction of phosphate
intake did not increase the levels of calcitriol. In these studies,
we observed a signiﬁcant decrease in serum-ionized Ca and
phosphate conditions known to stimulate 1a-hydroxylase,
but plasma calcitriol did not increase. Finally, in 1996
(ref. 13) we demonstrated in vitro that phosphate per se,
independent of ionized calcium or calcitriol, has a direct
effect on PTH secretion. Parathyroid glands obtained from
normal rats were incubated in vitro with culture media
containing 0.2 or 2.8mmol/l phosphorus. Again, the concen-
trations of ionized calcium and calcitriol were the same
in both situations. The 2.8mmol/l phosphorus concentration
in the media greatly increased the secretion of PTH in
comparison with the results obtained with 0.2mmol/l
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Figure 3|Comparison of tubular reabsorption of phosphate
(TRP) and glomerular filtration rate (GFR) in a group of
normal subjects and 24 patients with different degrees of
chronic kidney disease. The lower the GFR, the lower the TRP or
the greater the excretion of phosphate per nephron. Reproduced
by permission from Slatopolsky et al.
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American Society for Clinical Investigation. Reproduced with
permission from the American Society for Clinical Investigation in
the format Journal via Copyright Clearance Center.
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Figure 4|Effects of a low-phosphate, low-calcium diet on serum calcium, calcitriol, phosphorus, and parathyroid hormone (PTH)
in dogs with chronic kidney disease and established secondary hyperparathyroidism. *po0.05. Figure newly constructed from
data in Lopez-Hilker et al.
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14,15
clearly demonstrated a direct effect of phosphate on PTH
secretion. The effect of phosphate on the secretion of PTH is
posttranscriptional.
16,17 Figure 6 summarizes the mechan-
isms involved in the pathogenesis of secondary hyperpar-
athyroidism.
I believe it is important to emphasize that the initial
hypothesis regarding the mechanisms by which phosphate
controls the regulation of PTH was made 50 years ago, and
since then many factors have been discovered that also
participate in the regulation of PTH. Regardless of these new
developments, the initial idea that phosphate per se
controls PTH is correct.
PHOSPHATE–PARATHYROID–INTESTINAL–RENAL AXIS
Several studies in experimental animal models have shown
that a high phosphate intake can accelerate uremia-induced
parathyroid hyperplasia and secondary hyperparathyroidism,
whereas phosphate restriction prevents these abnormalities.
The effect of phosphate is independent of serum calcium and
1,25(OH)2D3 (refs 13, 18).
We conducted further studies in uremic rats with
established parathyroid hyperplasia and secondary hype-
rparathyroidism to determine whether the change to a
low-phosphate diet could modify the above abnormalities.
19
After 1 week of a low-phosphate diet, serum PTH returned to
normal despite the persistence of parathyroid hyperplasia.
Our studies did not show a change in the synthesis of
PTH, but did show a suppression of PTH release. We also
demonstrated an increase in intracellular PTH in the
parathyroid gland in animals that were fed a high-phosphate
diet and subsequently treated for 1 week with a low-phos-
phate diet. No apoptosis was observed in these glands.
Because of our ﬁndings, we called our studies ‘Hyperplasia
of the parathyroid glands without secondary hyperpara-
thyroidism.’
19
Studies by Ritter et al.
20 in our laboratory demonstrated
that after 2 weeks of CKD and a high-phosphate diet there
was a signiﬁcant loss of the calcium-sensing receptor.
However, when the diet was switched to one that was lower
in phosphate, serum PTH returned to normal in only 1 day
but it took B2 weeks for the calcium-sensing receptor to
return to normal.
Further studies by Martin et al.
21 in our laboratory
demonstrated that in rats with established secondary
hyperparathyroidism there was a 60–80% decrease in serum
phosphorus and PTH, with no change in serum calcium only
2h after feeding the uremic rats a low-phosphate diet.
Moreover, when a low-phosphate diet was given by gavage,
serum PTH and phosphorus decreased signiﬁcantly after only
15min. On the other hand, when serum phosphate was
acutely decreased by an infusion of glucose, no change in
serum PTH was observed. All these results raise the question,
‘Is there an acute regulation of PTH by dietary phosphate,
and if so, is it mediated by a hormone possibly derived from
the gastrointestinal tract?’
Recently, Berndt et al.
22 demonstrated that the instillation
of phosphate in the duodenum of normal rats rapidly
increases the renal excretion of phosphate. This was also seen
in thyroparathyroidectomized rats, and there were no
changes in the ﬁltered load of phosphate or serum levels of
FGF-23 or secreted frizzled-related protein. Moreover, these
observations were also seen when the kidney was denervated,
and the phosphaturia was not elicited when phosphate was
instilled in other parts of the gastrointestinal tract, such as
the stomach. Furthermore, when homogenates of duodenal
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Figure 5|The effects of phosphorus in the culture media on
the secretion of parathyroid hormone (PTH) in a normal rat
parathyroid gland in vitro. In the two experimental conditions,
the concentrations of ionized calcium and 1,25(OH)2D3 were
identical. Error bars denote standard error. Adapted with
permission from Slatopolsky et al.
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Figure 6|Summary of the factors involved in the
pathogenesis of secondary hyperparathyroidism. A decrease
in ionizing calcium (ICa) is crucial in the development of
secondary hyperparathyroidism. This change in ICa is secondary
to phosphate retention and to low levels of 1,25(OH)2D3.
Phosphate retention increases fibroblast growth factor (FGF)-23,
which, in conjunction with its cofactor, the Klotho protein,
decreases the activity of the 1a-hydroxylase and increases the
24a-hydroxylase, thus decreasing the levels of circulating
1,25(OH)2D3. In addition, phosphate retention, independent of
change in ICa, posttranscriptionally increases the synthesis of
parathyroid hormone (PTH). The 1,25(OH)2D3, independent of
calcium, suppresses the transcription of the PTH gene. Decreases
in the vitamin D receptor, calcium sensor receptor, and
Klotho–FGFR1 receptor complex in the parathyroid gland also
aggravate the development of secondary hyperparathyroidism.
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in renal phosphate excretion. Berndt et al.
22 believe that there
is a direct existence of an intestinal–renal axis speciﬁc for
phosphate that is mediated by an unknown factor ‘intestinal
phosphatonin’. Moreover, they also propose the existence of
an intestinal phosphate sensor.
23 Although this sensor has
not yet been demonstrated, it is possible that the parathyroid
gland also has a ‘phosphate sensor’. Again, to date there is no
scientiﬁc proof for the existence of such a sensor. This author,
however, strongly believes in the existence of a ‘phosphate
sensor’ in parathyroid glands. To date, all the important
factors that control the release of PTH have a sensor in the
parathyroid gland (that is, vitamin D receptor, calcium
sensor receptor, Klotho–FGFR-1 receptor complex), and as
phosphate also has a crucial role in the development of
secondary hyperparathyroidism the existence of a phosphate
sensor seems to be a reasonable possibility.
PHOSPHATE MODULATION OF PARATHYROID HYPERPLASIA
Parathyroid cell proliferation rather than hypertrophy is the
main determinant of parathyroid enlargement and secondary
hyperparathyroidism. The lack of an appropriate parathyroid
cell line has impeded the identiﬁcation of the mechanisms
underlying the switch from a quiescent parathyroid cell
to one that divides rapidly in response to hypocalcemia,
hyperphosphatemia, or a decrease in 1,25(OH)2D3 as part of
the progression of CKD. Studies conducted by Dusso et al.
24
centered on phosphate control of parathyroid cell prolifera-
tion, as no change in the number of cells undergoing
apoptosis has been observed in experimental conditions
affecting parathyroid cells.
19 Dusso et al.
24 focused on dietary
phosphate regulation of parathyroid expression of the cyclin/
cyclin-dependent kinase inhibitor p21. Her studies demon-
strate that, in early CKD, phosphate restriction may arrest
uremia-induced parathyroid hyperplasia through a speciﬁc
induction of the mRNA and protein levels of the cyclin-
dependent kinase inhibitor p21. In addition, high phosphate
intake induces transforming growth factor (TGF)-a, which
seems to function as an autocrine signal to stimulate cell
growth, thus worsening the parathyroid hyperplasia and the
resultant secondary hyperparathyroidism. Growth signals
from enhanced parathyroid TGF-a require activation of
the epidermal growth factor receptor (EGFR): a 170-kDa
membrane glycoprotein with intrinsic tyrosine kinase
activity.
25 TGF-a-activated EGFR translocates to the nucleus,
where it functions as a transcription factor. TGF-a/EGFR-
driven growth involves TGF-a binding to the EGFR, which in
turn induces EGFR dimerization and tyrosine phosphoryla-
tion of the EGFR by an intrinsic EGFR tyrosine kinase. This
step is critical for the onset of downstream growth signal.
Studies conducted by Cozzolino et al.
26 clearly demonstrate
that a high phosphate dietary intake increases not only
TGF-a but also the EGFR in the parathyroid gland of rats with
CKD. The TGF-a–EGFR complex produces growth acceleration
of benign and malignant tissue. Moreover, in the same studies,
26
the use of erlotinib, a tyrosine kinase inhibitor, counteracted the
potent mitogenic signals triggered by kidney disease and
phosphate retention. Low-calcium diets also increase the
TGFa–EGFR complex. This study
26 demonstrates that the
enhancement of parathyroid TGF-a and EGFR expression and
growth signal occurs early after the onset of renal disease and is
aggravated by a high-phosphate or a low-calcium diet.
Further studies by Dusso et al.
27 identify a tumor necrosis
factor-a-converting enzyme (TACE) as the cause of the initial
increase in parathyroid TGF-a, and this starts the vicious
cycle for progression of parathyroid hyperplasia. TACE, also
known as ADAM17, is a metalloproteinase essential for TGF-
a signaling and several other EGFR ligands. The location of
TACE at the cell membrane is mandatory for its function.
Preliminary results
27 in uremic rats have shown that high
phosphate intake also enhances parathyroid TACE content in
early and established secondary hyperparathyroidism. How-
ever, high dietary phosphate may not affect parathyroid
TACE expression directly, but may induce its translocation to
the cell surface, causing the release of TGF-a required to
initiate EGFR activity during parathyroid cell growth and
TACE stabilization.
CONCLUSIONS
The intact nephron hypothesis has fueled 50 years of research
and discovery in CKD. The adverse events of hyperphos-
phatemia in CKD, secondary hyperparathyroidism, calcium
and vitamin D derangements, vascular calciﬁcation, and
metabolic bone disorder are the results of the endocrine
trade-offs required by the adaptation of nephrons attempting
to preserve phosphate homeostasis. Restricting phosphate
intake or, when that is not possible, restricting phosphate
absorption by use of phosphate binders as GFR declines
reduces the need for nephron adaptation and forestalls
endocrine sequelae such as hyperparathyroidism. PTH is
regulated at the levels of mRNA stability and protein
exocytosis by extracellular phosphate concentration. Rapid
(15-min) regulation of PTH by phosphate may require the
release of an intestinal hormone. The increase in fractional
excretion of phosphate after the instillation of phosphate in
the intestine is rapid (15–20min) and does not require PTH
or FGF-23. Potentially, an ‘intestinal phosphatonin’ may be
the mediator of this action. Finally, in the parathyroid gland,
enhanced TGF-a and EGFR coexpression drives parathyroid
hyperplasia in early CKD. Parathyroid TACE activity, itself
controlled by phosphate and vitamin D, is crucial in
transducing these growth signals and will be an important
therapeutic target. Clearly, phosphate has direct effects at
multiple organ sites suggesting a phosphate sensor. However,
further studies are necessary to scientiﬁcally prove the
existence of a phosphate sensor in the parathyroid glands
and gastrointestinal tract.
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